BridgeBio Pharma
BBIO
BBIO
161 hedge funds and large institutions have $8.37B invested in BridgeBio Pharma in 2020 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 64 increasing their positions, 37 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
25% more funds holding
Funds holding: 129 → 161 (+32)
2.37% more ownership
Funds ownership: 96.31% → 98.68% (+2.4%)
Holders
161
Holding in Top 10
12
Calls
$27.7M
Puts
$8.42M
Top Buyers
| 1 | +$55.3M | |
| 2 | +$38.7M | |
| 3 | +$32.7M | |
| 4 |
BlackRock
New York
|
+$28.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.5M |
Top Sellers
| 1 | -$13.2M | |
| 2 | -$8.75M | |
| 3 | -$7.11M | |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$4.94M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.12M |